With four promising programs in the pipeline, ACER should be your portfolio’s ace in the hole
With so many biotechnology firms to choose from, it’s important for investors to be ultra-selective and only pick the ones that truly stand out. Fortunately, the leadership’s qualifications, advanced clinical pipeline, and clear pathways to regulatory approval set Acer Therapeutics Inc. (ACER) apart.
Each of Acer’s four clinical programs really deserves its own separate discussion. Together, they present a robust suite of potential therapies for a broad class of patients with serious yet largely unmet medical needs.
That’s a shame, but it’s a fact of life that too many biotechnology companies tend to focus on more common ailments. Acer, meanwhile, dares to ambitiously pursue treatments for those among us who suffer from serious rare and life-threatening diseases.
Sure, there’s a Covid connection with ACER stock, and we’ll certainly address this angle. However, through a deeper analysis we’ll discover that Acer’s commitment to underappreciated demographics – and sufficiently strong cash position to attain its objectives – will serve all stakeholders well in the coming years.
A Closer Look at ACER Stock
You definitely don’t want to sleep on ACER stock as it’s proven time and again that it could spike hard at any given moment, completely without warning.
That’s great news if you’re not yet positioned with ACER stock. Not just once but on three separate occasions, the ACER stock bulls made a swift run towards the $5 level.
In other words, ACER stock could easily double within a matter of days. There’s no point in waiting for a run-up to start, as before you know it, ACER will already have made its move and you’ll have missed the proverbial bus.
By the end of the trading day on December 18, ACER stock was sitting pretty at $2.69. The stock had gained nearly 10% in just that single trading session. So, prepare for a possible liftoff with ACER stock – you won’t know when it’s coming, but you’ll surely know it when you get there.
Small but Powerful
With a head count of just 19, no one is claiming that Acer is the biggest biotech on the block. That can work in the company’s favor, however, as Acer’s team remains lean and committed to the cause.
Besides, no one can reasonably dismiss the deep-level expertise and experience of Acer’s leadership team:
- CEO and Founder Chris Schelling: 21 years of strategic commercial development and orphan drug company experience
- Chief Operating and Financial Officer Harry Palmin: 25+ years of corporate and finance experience
- Chief Commercial Officer Matt Seibt: 22 years of sales, market access and product launch experience
- VP of Clinical Operations Stacey Bain: 22 years of clinical operations and drug development experience
- VP of Regulatory Affairs Renee Carroll: 25+ years of regulatory affairs experience at all phases of development
Founded in December of 2013, Acer is about as well-capitalized as one could expect a tiny biotech company to be during a global pandemic.
As of September 30, 2020, Acer had $6.2 million in cash combined with additional $1 million in proceeds subsequently received from ATM stock sales and a stock purchase agreement with Lincoln Park Capital.
Don't Miss The Next Big Story
Join our free mailing list below to receive real-time news alerts and our next featured stock!Safety and Effectiveness
Even beyond the star-studded leadership and the excellent capital position, what’s particularly encouraging about Acer is the company’s commitment to treatment alternatives that are both effective and safe.
Acer’s pipeline includes four programs:
• Emetine Hydrochloride for the treatment of Covid-19. Preclinical phase; third-party studies have shown broad-acting anti-viral inhibition
• ACER-001 (a taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCD’s) and Maple Syrup Urine Disease (MSUD). Already at Phase 3 for urea cycle disorders; also at Phase 1 for Maple Syrup Urine Disease
• EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation. Shown to induce vascular dilatation and smooth muscle relaxation; already at Phase 3
• Osanetant for the treatment of induced Vasomotor Symptoms (iVMS) – Preclinical phase.
It might be tempting to focus entirely on the Emetine Hydrochloride program, for which Acer aims to submit an Investigational New Drug Application (IND) followed by potential clinical trial initiation in H1 2021.
Yet, let’s not ignore the favorable safety profiles of all four product programs, which ultimately de-risk Acer as a medical solution provider and ACER stock as an investment. Even with substantial evidence of effectiveness, Acer can be counted on to discontinue the research process of any product if the risk/benefit profile no longer justifies the commitment of resources.
The Bottom Line
Biopharmaceutical companies don’t have to be the biggest in order to be the best of the bunch. Sometimes, a small yet dedicated team can stun the scientific community with incredible achievements.
Quality, not size, will be the key to success for Acer Therapeutics and ACER stock as leadership, capital, and dedication remain the pillars of progress for stakeholders and patients alike.
